UK's Creo Medical H1 revenue surges, loss narrows

Overview

• UK medical device firm's H1-26 revenue rose 45% yr/yr, in line with management expectations

• Underlying operating loss for H1-26 narrowed by over 25% to £4.9 mln

• Company completed £5.5 mln equity placing and secured £2 mln convertible loan note in May 2026

Outlook

• Creo Medical expects full-year revenue growth of 50% to 60%

• Company says H2 revenue profile is supported by a strong order book and usual seasonality

• Company expects proceeds from CME Stake Disposal to strengthen near-term balance sheet

Result Drivers

• PROCEDURAL ADOPTION - Co said revenue growth was supported by increased adoption of its advanced energy platform and broader clinician engagement

• COST CONTROL - Co attributed reduced operating costs to disciplined cost control and a simplified operating model

• CLINICAL VALIDATION - Co said growing external clinical validation and key opinion leader presentations supported commercial adoption

Company press release:

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "strong buy"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Creo Medical Group PLC is GBp55.00, about 363.2% above its September 29 closing price of GBp11.88

Reuters Recommended Reads

• Sept 29 - UK's Billington Holdings H1 profit jumps 70% on data centre demand

• Sept 28 - Betting firms Flutter and Entain warn of hit from Brazil's online betting ban

• Sept 28 - Tullow Oil swings to positive free cash flow as Ghana output, higher oil prices drive growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)